semaglutide restrictions A GLP-1 medication you swallow — no needle, no food — just had its first head-to-head trial results published. Orforglipron (Foundayo, Eli Lilly) was FDA-approved April 2026. In July 2026, the Understanding Eligibility for Ozempic Medical

Fibrotic encapsulation is the dominant source of continuous glucose monitor delays

16 Finally, compared to other GLP-1 receptor agonists like dulaglutide, semaglutide is generally more potent, longer-acting, and often leads to greater HbA1c reductions and weight loss

These flavor-packed options represent convenience, comfort, and cultural connection that generic diets would eliminate completely

In the phase 2 dose-escalation study (Jastreboff et al., NEJM, 2023), gastrointestinal adverse events were reported in a substantial proportion of participants, with incidence increasing at higher doses

Advocates say if cats need to be removed, there is typically a process involving animal control, microchip checks and relocation to a verified rescue or sanctuary

Participants in the study who received glp-1 in conjunction with lifestyle intervention experienced an average weight loss of around 15% of their body weight within one year